Clinical Trials at Smilow Cancer Hospital Care Center - Waterford

As of July 2026, 45 paid clinical trials are recruiting at Smilow Cancer Hospital Care Center - Waterford in Waterford, Connecticut. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

45 clinical trials at Smilow Cancer Hospital Care Center - Waterford

·Clear filters·↓ Download CSV

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

for Retroperitoneal Sarcoma

109 locations incl. Birmingham

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Sex: All·Age: 18+

Code: NCT04031677·Phase 3·Recruiting

Apply to this trial

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

for HER2-positive Metastatic Breast Cancer

37 locations incl. San Francisco

Sponsor: Abramson Cancer Center at Penn Medicine

Sex: All·Age: 18+

Code: NCT06551116·Recruiting

Apply to this trial

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

for Resectable Intrahepatic Cholangiocarcinoma

Drug: Durvalumab

58 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06050252·Phase 2·Recruiting

Apply to this trial

Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

for Non-small Cell Lung Cancer

6 locations incl. Greenwich

Sponsor: Yale University

Sex: All·Age: 18+

Code: NCT04210492·Phase 1, Phase 2·Recruiting

Apply to this trial

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

for Locally Recurrent Skin Squamous Cell Carcinoma

Drug: Amivantamab

38 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07042295·Phase 2·Recruiting

Apply to this trial